Stock Track | 4DMedical Soars 5.00% Intraday on FDA Approval and US$1.1 Billion Market Potential

Stock Track

03/02

4DMedical Limited's stock surged 5.00% during Monday's intraday trading session, reflecting heightened investor interest in the medical imaging company.

The significant price movement appears to be driven by recent developments regarding the company's CT:VQ imaging platform. According to recent reports, 4DMedical has received FDA 510(k) clearance and CMS reimbursement approval for its CT:VQ product, positioning it for commercial deployment in the United States.

The company has highlighted an initial addressable U.S. market exceeding US$1.10 billion annually for the newly approved CT:VQ imaging technology. This substantial market opportunity, combined with regulatory clearance, has likely contributed to investor optimism about the company's growth prospects despite recent financial results showing continued investment in product development and commercialization.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/1154718745"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1154718745\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1154718745?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-02 08:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1154718745","market":"us","top_or_hot":-1,"title":"Stock Track | 4DMedical Soars 5.00% Intraday on FDA Approval and US$1.1 Billion Market Potential","media":"Stock Track","content":"<p>4DMedical Limited's stock surged 5.00% during Monday's intraday trading session, reflecting heightened investor interest in the medical imaging company.</p><p>The significant price movement appears to be driven by recent developments regarding the company's CT:VQ imaging platform. According to recent reports, 4DMedical has received FDA 510(k) clearance and CMS reimbursement approval for its CT:VQ product, positioning it for commercial deployment in the United States.</p><p>The company has highlighted an initial addressable U.S. market exceeding US$1.10 billion annually for the newly approved CT:VQ imaging technology. This substantial market opportunity, combined with regulatory clearance, has likely contributed to investor optimism about the company's growth prospects despite recent financial results showing continued investment in product development and commercialization.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | 4DMedical Soars 5.00% Intraday on FDA Approval and US$1.1 Billion Market Potential</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | 4DMedical Soars 5.00% Intraday on FDA Approval and US$1.1 Billion Market Potential\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-03-02 08:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>4DMedical Limited's stock surged 5.00% during Monday's intraday trading session, reflecting heightened investor interest in the medical imaging company.</p><p>The significant price movement appears to be driven by recent developments regarding the company's CT:VQ imaging platform. According to recent reports, 4DMedical has received FDA 510(k) clearance and CMS reimbursement approval for its CT:VQ product, positioning it for commercial deployment in the United States.</p><p>The company has highlighted an initial addressable U.S. market exceeding US$1.10 billion annually for the newly approved CT:VQ imaging technology. This substantial market opportunity, combined with regulatory clearance, has likely contributed to investor optimism about the company's growth prospects despite recent financial results showing continued investment in product development and commercialization.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"4DX.AU","symbol_name":"4DMEDICAL LTD","start_time":0,"source_url":"","article_id":"1154718745","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1154718745","pubTimestamp":1772410109,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"4DMedical Limited's stock surged 5.00% during Monday's intraday trading session, reflecting heightened investor interest in the medical imaging company.The significant price movement appears to be...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"4DX.AU":"4DMEDICAL LTD"},"translate_title":"个股追踪|4DMedical盘中大涨5.00%获FDA批准及11亿美元市场潜力","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"4DX.AU":1},"content_text":"4DMedical Limited's stock surged 5.00% during Monday's intraday trading session, reflecting heightened investor interest in the medical imaging company.The significant price movement appears to be driven by recent developments regarding the company's CT:VQ imaging platform. According to recent reports, 4DMedical has received FDA 510(k) clearance and CMS reimbursement approval for its CT:VQ product, positioning it for commercial deployment in the United States.The company has highlighted an initial addressable U.S. market exceeding US$1.10 billion annually for the newly approved CT:VQ imaging technology. This substantial market opportunity, combined with regulatory clearance, has likely contributed to investor optimism about the company's growth prospects despite recent financial results showing continued investment in product development and commercialization.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}